Abstracts Archive - Page 104 of 2607 - ACR Meeting Abstracts

Abstract Number: 1019 • ACR Convergence 2025
Associations Between Mental Health Diagnoses and Acute Care Use Among Individuals with Systemic Lupus Erythematosus in the All of Us Research Program
Karen H. Costenbader¹, Jeong Yee², Hongshu Guan³, Emily Oakes⁴, Jing Cui³, Leah Santacroce⁴, Elizabeth Karlson⁴, Karestan Koenen⁵, Laura Kubzansky⁵ and Candace Feldman³, ¹Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ²Sungkyunkwan University, Suwon, MA, South Korea, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Harvard T.H Chan School of Public Health, Boston
Background/Purpose: Mental health disorders, including depression, anxiety, and post-traumatic stress disorder, are prevalent among people with SLE. In other disease populations, these disorders have been…
Abstract Number: 1104 • ACR Convergence 2025
Immune Checkpoint Inhibitors and Cardiovascular Risk in Patients with Rheumatoid Arthritis and Cancer
Kevin Sheng-Kai Ma¹, Rachael Stovall², Jeffrey Sparks³, You Wu², Richard Cheng⁴, Gregory Challener⁵, Hans von Eckstaedt², Bhavik Bansal⁶, Petros Grivas⁷, Steven Chen⁸, Jean Liew⁹ and Namrata Singh⁷, ¹Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Philadelphia, PA, ²University of Washington, Seattle, WA, ³Brigham and Women's Hospital, Boston, MA, ⁴University of Washington, Seaattle, WA, ⁵MGH, Boston, MA, ⁶UT Southwestern Medical Centre, Dallas, TX, ⁷University of Washington, BELLEVUE, WA, ⁸Massachusetts General Hospital, Boston, ⁹Boston University, Boston, MA
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) face a higher lifetime burden of cardiovascular disease (CVD) vs the general population with approximately 1.5-2-fold increase in…
Abstract Number: 1119 • ACR Convergence 2025
Microbial activation of cytotoxic CD8⁺ T cells promotes skin immune-related adverse events in patients treated with immune checkpoint inhibitors
Shady Younis¹, Suman Acharya¹, Gayathri Swaminathan¹, Heidi Wong¹, Hannah Kim¹, Alec Eschholz¹, Subramanya Hegde², Andrew McKnight³, William Robinson⁴ and Lisa Zaba¹, ¹Stanford University, Stanford, CA, ²Sanofi US, New Jersey, MA, ³Sanofi US, Cambridge, MA, ⁴Stanford University, Palo Alto, CA
Background/Purpose: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their use is often limited by immune-related adverse events (irAEs), particularly in barrier tissues such…
Abstract Number: 1105 • ACR Convergence 2025
Association between pre-existing rheumatoid arthritis and immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors
Kevin Sheng-Kai Ma¹, You Wu², Rachael Stovall², Jean Liew³ and Namrata Singh⁴, ¹Center for Global Health, Perelman School of Medicine, Philadelphia, PA, ²University of Washington, Seattle, WA, ³Boston University, Boston, MA, ⁴University of Washington, Bellevue, WA
Background/Purpose: Immune checkpoint inhibitors (ICIs), widely used to treat a variety of cancers, are associated with immune-related adverse events (irAEs) that are increasingly encountered in…
Abstract Number: 1099 • ACR Convergence 2025
Safety and Effectiveness of Hydroxychloroquine in the Treatment of Rheumatic Immune-Related Adverse Events
Grace Haeun Lee¹, Gregory Challener², Janeth Yinh³, Jeffrey Sparks⁴, Kerry L. Reynolds⁵, Donald P. Lawrence⁵, Meghan J. Mooradian⁵, Ryan J. Sullivan⁵, Hyon K. Choi⁶ and Minna Kohler⁷, ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Massachusetts General Hospital, Boston, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁷Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) has been recommended [1-3] as a steroid-sparing agent for immune checkpoint inhibitor-inflammatory arthritis (ICI-IA), preferred due to its low immunosuppressive effect. However,…
Abstract Number: 1126 • ACR Convergence 2025
Clinical Impact of Signs of Calcium Pyrophosphate Deposition Disease (CPPD) on Radiographs of Hands and Wrists in a Real-World Cohort of Patients with Early Rheumatoid Arthritis
Coralie Tremblay¹, Nathalie Carrier², Hugues Allard-Chamard³, Javier Marrugo⁴, Sophie Roux⁴, Gilles Boire⁵ and Ariel Masetto⁴, ¹Université de Sherbrooke, Division of Rheumatology, Department of Medicine and Health Sciences, Sherbrooke, Canada, and Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS), Sherbrooke, Canada, Saint-Augustin-de-Desmaures, QC, Canada, ²Centre integré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie-CHUS), Sherbrooke, Canada, ³Université de Sherbrooke, Sherbrooke, Canada, ⁴Université de Sherbrooke, Division of Rheumatology, Department of Medicine and Health Sciences, Sherbrooke, Canada, and Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS), Sherbrooke, Canada, Sherbrooke, Canada, ⁵Retired, Sherbrooke, QC, Canada
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a common cause of arthropathy over the age of 60. It can also manifest as a chronic polyarticular…
Abstract Number: 1124 • ACR Convergence 2025
ABCG2 Variants as Genetic Risk Factors for Hyperuricemia and Gout: Focus on Pediatric and Familial Manifestations
Blanka Stiburkova¹, katerina pavelcova², Jana masinova³, Pavel Jesina⁴, Yu Toyoda⁵ and Tappei Takada⁵, ¹Institute of Rheumatology, Praha ¹⁰, Czech Republic, ²Institute of Rheumatology, Praha ², Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, ⁴Revmatologický ústav, Praha ², Czech Republic, ⁵The University of Tokyo Hospital, Tokyo, Japan
Background/Purpose: Gout, a condition arising from hyperuricemia, is considered as both a metabolic disorder and an autoinflammatory disease. Genetic factors are estimated to contribute approximately…
Abstract Number: 1125 • ACR Convergence 2025
Validation of an Allopurinol Dose Prediction Tool to Achieve Goal Serum Urate Among Patients with Gout
Brian Coburn¹, Daniel Wright², Jeff Newcomb³, Mary Brophy⁴, Anne Davis-Karim⁵, Ryan Ferguson⁴, Michael Pillinger⁶, Tuhina Neogi⁷, Paul Palevsky⁸, Bryant England³, James O'Dell³, Lisa Stamp⁹, Ted Mikuls³ and Joshua Baker¹⁰, ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Otago, Dunedin, New Zealand, ³University of Nebraska Medical Center, Omaha, NE, ⁴VA Cooperative Studies Program Coordinating Center, Boston, MA, ⁵VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ⁶New York University Grossman School of Medicine, New York,, NY, ⁷Boston University School of Medicine, Boston, MA, ⁸VA Pittsburgh Healthcare System, Pittsburgh, PA, ⁹University of Otago, Christchurch, Christchurch, New Zealand, ¹⁰University of Pennsylvania, Philadelphia, PA
Background/Purpose: Despite evidence-based recommendations, allopurinol dose escalation to goal serum urate (SU) is frequently suboptimal. The EasyAllo tool was developed to facilitate pre-planned allopurinol dose…
Abstract Number: 1083 • ACR Convergence 2025
How Do Social Determinants of Health Differ Across Age and Disability Groups Among Adult Medicare Advantage Enrollees with Systemic Lupus Erythematosus?
Alexjandro Daviano¹, Vijay R. Nadipelli², Yihua Xu¹, Karen Worley², Shireen Haq¹, Josephine Ohioma³, Jeffrey J. Ellis², Brandon T. Suehs¹ and S. Sam Lim⁴, ¹Humana Healthcare Research, Inc., Louisville, KY, ²GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA, ³GSK, US Medical Affairs, Philadelphia, PA, ⁴Emory University School of Medicine, Atlanta, GA
Background/Purpose: Management of patients with SLE should consider social determinants of health (SDoH) and their impact on access, treatment, and patient outcomes; however, such a…
Abstract Number: 1091 • ACR Convergence 2025
Safety Profile of ICIs in Patients with Rheumatoid Arthritis: Results from a Propensity Score-Matched Cohort Study
Betul Ibis¹, Furkan Bahar¹, Yu-Che Lee², Ko-Yun Chang³, Yu Chang⁴ and Cho-Han Chiang⁵, ¹Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, ²University at Buffalo, Buffalo, NY, ³National Jewish Health, Denver, CO, ⁴National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China), ⁵Mount Auburn Hospital, Harvard Medical School, Cambridge
Background/Purpose: Immune-related adverse events (irAEs) are a significant concern for patients receiving immune checkpoint inhibitors (ICIs), particularly those with pre-existing rheumatoid arthritis (RA). Managing ICIs…
Abstract Number: 1101 • ACR Convergence 2025
Distinct Clinical Phenotypes of Immune Checkpoint Inhibitor–Associated Arthritis: Comparative Analysis of Inflammatory Arthritis, Polymyalgia Rheumatica-like, Activated Crystalline, and Activated Osteoarthritis
Heba Altarawneh¹, Gregory Challener², Mazen Nasrallah³, Janeth Yinh⁴, Hyon K. Choi⁵ and Minna Kohler⁶, ¹Mass General Hospital, Boston, MA, ²MGH, Boston, MA, ³MGB-Salem Hospital, Lynn, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁶Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Immune checkpoint inhibitor (ICI)–associated arthritis has been classified into distinct phenotypes, including inflammatory arthritis (IA), polymyalgia rheumatica (PMR)-like syndrome, activated crystalline arthritis, and activated…
Abstract Number: 1030 • ACR Convergence 2025
Predictors of Incident Atrial Fibrillation in Rheumatoid Arthritis Patients: A Population Based Cohort Study
Sarah Pimple¹, Alanna Chamberlain¹, Sara Achenbach², Cynthia Crowson³ and Elena myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Rheumatoid arthritis (RA) has been associated with an increased risk of developing atrial fibrillation (AF). However, recent data on trends in incidence of AF…
Abstract Number: 1133 • ACR Convergence 2025
A Proteomic Analysis Of Subclinical Synovial Inflammation Associated With Monosodium Urate Crystal Deposition
Mariano Andrés¹, María-Luisa Peral-Garrido², Samanta Ortuño³, Rocío Caño³, Silvia Gómez-Sabater³, Alejandra Bermúdez⁴, Teresa Lozano⁵, Miguel Perdiguero⁵, elena Caro-Martínez⁶, Ruth Sánchez-Ortiga⁵, Carolina Ruiz-García⁷, Eliseo Pascual⁸ and Rubén Francés⁸, ¹Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ²Vinalopó University Hospital, Novelda, Spain, ³Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, ⁴Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ⁵Dr Balmis General University Hospital, Alicante, Spain, ⁶HACLE San Vicente Hospital, San Vicente del Raspeig, Spain, ⁷Campoamor Health Center, Alicante, Spain, ⁸Miguel Hernandez University of Elche, Alicante, Spain
Background/Purpose: Persistent subclinical inflammation from monosodium urate (MSU) crystals is present in gout and asymptomatic hyperuricemia (AH). The underlying mechanism is poorly understood. This study…
Abstract Number: 1134 • ACR Convergence 2025
Efficacy and Safety of Anakinra for Acute Calcium Pyrophosphate Deposition Disease Flare: A Systematic Review and Meta-Analysis
Pannathorn Nakaphan¹, Somkiat Phutinart², Patavee Pajareya², Priabprat Jansem³, Nattanicha Chaisrimaneepan⁴, Pim Jetanalin⁵ and Noppachai Siranart², ¹Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, ²Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, ³Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand, ⁴Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ⁵Department of Medicine, Division of Rheumatology, University of Illinois College of Medicine, Chicago, IL
Background/Purpose: Calcium Pyrophosphate Deposition Disease (CPPD) is a common inflammatory arthritis among older adults. Comorbidities often limit conventional treatment of acute CPPD flare. Anakinra, an…
Abstract Number: 1076 • ACR Convergence 2025
Racial Differences in Real-World Use of Urate-Lowering and Adjunctive Therapies for Gout: A 10-Year Propensity-Matched Cohort Study
Michael Hamilton¹, Justin Riley Lam², Emmanuel Otabor³, Laith Alomari³, Maxim Barnett³, Arthur Lau⁴ and Irene Tan⁵, ¹Jefferson Einstein Hospital, Philadelphia, Philadelphia, PA, ²Jefferson Einstein Hospital, Philadelphia, PA, ³Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ⁴Jefferson Einstein Hospital, Maple Glen, PA, ⁵Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Although achieving target serum urate (SU) and reducing cardiovascular events are cornerstones of gout management, little is known about contemporary treatment patterns across racial…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].